ONX-0914

Ligand id: 9031

Name: ONX-0914

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 17
Topological polar surface area 138.6
Molecular weight 580.29
XLogP 2.92
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
(2S)-3-(4-methoxyphenyl)-N-[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide
Synonyms
PR-957
Database Links
PubChem CID 23642227
Search Google for chemical match using the InChIKey WQAVPPWWLLVGFK-VTNASVEKSA-N
Search Google for chemicals with the same backbone WQAVPPWWLLVGFK
Search UniChem for chemical match using the InChIKey WQAVPPWWLLVGFK-VTNASVEKSA-N
Search UniChem for chemicals with the same backbone WQAVPPWWLLVGFK
Comments
Proteolix (later Onyx Pharmaceuticals, now Amgen) developed the peptidomimetic inhibitor PR-957 (ONX-0914), which selectively inhibited the chymotrypsin-like activity of LMP7. This blocked presentation of LMP7-specific, MHC-I-restricted antigens and reduced immunoproteasome production of pro-inflammatory cytokines such as IL-6, IFN-γ, TNF-α and IL-23 [1]. Note there are at least 6 isomeric alternatives for this structure including ChEMBL entries and SureChEMBL patent mappings (see "same connectivity" links in the PubChem CID entry).